{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T15:39:11Z","timestamp":1762011551338,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.atherosclerosis.2019.02.031","type":"journal-article","created":{"date-parts":[[2019,3,3]],"date-time":"2019-03-03T01:15:44Z","timestamp":1551575744000},"page":"202-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Circulating endostatin as a risk factor for cardiovascular events in patients with stable coronary heart disease: A CLARICOR trial sub-study"],"prefix":"10.1016","volume":"284","author":[{"given":"Toralph","family":"Ruge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel C.","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Kj\u00f8ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f8rgen","family":"Hilden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans J\u00f8rn","family":"Kolmos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Sajadieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Kastrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gorm Boje","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janus Christian","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Winkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6933-4637","authenticated-orcid":false,"given":"Johan","family":"\u00c4rnl\u00f6v","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.matbio.2010.11.001","article-title":"The multiple functions of collagen xviii in development and disease","volume":"30","author":"Seppinen","year":"2011","journal-title":"Matrix Biol."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/37126","article-title":"Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance","volume":"390","author":"Boehm","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","article-title":"Endostatin: an endogenous inhibitor of angiogenesis and tumor growth","volume":"88","author":"O'Reilly","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10555-008-9175-2","article-title":"Tumor stroma derived biomarkers in cancer","volume":"28","author":"Sund","year":"2009","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib5","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1161\/HYPERTENSIONAHA.113.02250","article-title":"Association between circulating endostatin, hypertension duration, and hypertensive target-organ damage","volume":"62","author":"Carlsson","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0929-6646(09)60133-9","article-title":"Pericardial fluid and serum levels of vascular endothelial growth factor and endostatin in patients with or without coronary artery disease","volume":"105","author":"Liou","year":"2006","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib7","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jacc.2003.10.063","article-title":"Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease","volume":"43","author":"Panchal","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.brainres.2009.11.033","article-title":"Endostatin expression in neurons during the early stage of cerebral ischemia is associated with neuronal apoptotic cell death in adult hypertensive rat model of stroke","volume":"1311","author":"Hou","year":"2010","journal-title":"Brain Res."},{"issue":"Suppl 2","key":"10.1016\/j.atherosclerosis.2019.02.031_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000089359","article-title":"Basic mechanisms in intracranial large-artery atherosclerosis: advances and challenges","volume":"20","author":"Arenillas","year":"2005","journal-title":"Cerebrovasc. Dis."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib10","doi-asserted-by":"crossref","first-page":"298239","DOI":"10.1155\/2014\/298239","article-title":"Serum endostatin concentrations are higher in men with symptoms of intermittent claudication","volume":"2014","author":"Golledge","year":"2014","journal-title":"Dis. Markers"},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib11","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1161\/ATVBAHA.113.301704","article-title":"Serum endostatin and risk of mortality in the elderly: findings from 2 community-based cohorts","volume":"33","author":"Arnlov","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/bmj.38666.653600.55","article-title":"Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: claricor trial","volume":"332","author":"Jespersen","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/jac\/dkp190","article-title":"Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the claricor trial","volume":"64","author":"Jespersen","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib14","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000128994","article-title":"Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the claricor randomized trial and updated meta-analysis of antibiotics for coronary heart disease","volume":"111","author":"Gluud","year":"2008","journal-title":"Cardiology"},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib15","first-page":"182","article-title":"Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10 years in the claricor randomised, blinded clinical trial","author":"Winkel","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib16","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jclinepi.2011.09.011","article-title":"Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart disease","volume":"65","author":"Kj\u00f8ller","year":"2012","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ahj.2013.12.032","article-title":"Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trial","volume":"168","author":"Kj\u00f8ller","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000324533","article-title":"Excess sudden cardiac deaths after short-term clarithromycin administration in the claricor trial: why is this so, and why are statins protective?","volume":"118","author":"Winkel","year":"2011","journal-title":"Cardiology"},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib20","doi-asserted-by":"crossref","DOI":"10.1186\/s41512-017-0009-y","article-title":"Predictors for major cardiovascular outcomes in stable ischaemic heart disease (premac): statistical analysis plan for data originating from the claricor (clarithromycin for patients with stable coronary heart disease) trial","author":"Winkel","year":"2017","journal-title":"Diagn. Prognostic Res."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1042\/CS20030365","article-title":"Serum levels of endostatin, vascular endothelial growth factor (vegf) and hepatocyte growth factor (hgf) in patients with acute myocardial infarction undergoing early reperfusion therapy","volume":"106","author":"Seko","year":"2004","journal-title":"Clin. Sci."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib22","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.ijcard.2012.03.075","article-title":"Reduced microvascular density in non-ischemic myocardium of patients with recent non-st-segment-elevation myocardial infarction","volume":"167","author":"Campbell","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib23","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.amjcard.2006.09.095","article-title":"Serum endostatin in the coronary circulation of patients with coronary heart disease and its relation to coronary collateral formation","volume":"99","author":"Mitsuma","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib24","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/MOL.0000000000000112","article-title":"Collagen and related extracellular matrix proteins in atherosclerotic plaque development","volume":"25","author":"Shami","year":"2014","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib25","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/emboj\/19.6.1187","article-title":"Secreted cathepsin l generates endostatin from collagen xviii","volume":"19","author":"Felbor","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib26","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.yexcr.2005.03.021","article-title":"Generation of biologically active endostatin fragments from human collagen xviii by distinct matrix metalloproteases","volume":"307","author":"Heljasvaara","year":"2005","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1096\/fasebj.13.1.9","article-title":"Vascular endothelial growth factor (vegf) and its receptors","volume":"13","author":"Neufeld","year":"1999","journal-title":"FASEB J."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib28","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib29","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/01.ATV.0000178991.71605.18","article-title":"Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage","volume":"25","author":"Virmani","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib30","first-page":"93","article-title":"Cardiac matrix remodelling in congestive heart failure: the role of matrix metalloproteinases","volume":"27","author":"Abou-Raya","year":"2004","journal-title":"Clin. Investig. Med."},{"issue":"Suppl A","key":"10.1016\/j.atherosclerosis.2019.02.031_bib31","doi-asserted-by":"crossref","first-page":"A13","DOI":"10.1253\/circj.CJ-08-0481","article-title":"Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure","volume":"72","author":"Oka","year":"2008","journal-title":"Circ J"},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1253\/circj.CJ-09-0486","article-title":"Inhibition of endostatin\/collagen xviii deteriorates left ventricular remodeling and heart failure in rat myocardial infarction model","volume":"74","author":"Isobe","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib33","doi-asserted-by":"crossref","first-page":"H428","DOI":"10.1152\/ajpheart.00283.2008","article-title":"Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation","volume":"296","author":"Sodha","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2019.02.031_bib34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.diabet.2016.03.006","article-title":"The association between endostatin and kidney disease and mortality in patients with type 2 diabetes","volume":"42","author":"Carlsson","year":"2016","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1159\/000369076","article-title":"Endostatin level is associated with kidney injury in the elderly: findings from two community-based cohorts","volume":"40","author":"Ruge","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib36","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/archsurg.143.5.463","article-title":"Increased antiangiogenic protein expression in the skeletal muscle of diabetic swine and patients","volume":"143","author":"Sodha","year":"2008","journal-title":"Arch Surg"},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2011.04.039","article-title":"Chronic type ii diabetes mellitus leads to changes in neuropeptide y receptor expression and distribution in human myocardial tissue","volume":"665","author":"Matyal","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib38","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Open-Label Study of Long-Term Evaluation against LDLCI. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2019.02.031_bib39","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915019301182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915019301182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:40:11Z","timestamp":1758156011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915019301182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":39,"alternative-id":["S0021915019301182"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.02.031","relation":{},"ISSN":["0021-9150"],"issn-type":[{"type":"print","value":"0021-9150"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating endostatin as a risk factor for cardiovascular events in patients with stable coronary heart disease: A CLARICOR trial sub-study","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.02.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}